Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020623384> ?p ?o ?g. }
- W2020623384 endingPage "542" @default.
- W2020623384 startingPage "531" @default.
- W2020623384 abstract "Background Soy protein (SP) and low-fat dairy product consumption have been suggested to have hypocholesterolemic effects, although the responsible mechanisms are poorly understood. Objective This randomized, controlled, parallel arm trial evaluated the effects of an insoluble fraction of SP and total milk proteins (TMPs) with high calcium content on the fasting lipid profile. It also assessed the potential contributions of increased excretion of bile acids and neutral sterols to their lipid-altering effects. Methods Subjects with hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] 100−199 mg/dL) followed the Therapeutic Lifestyle Changes diet for 4 weeks, followed by a 2-week lead-in with 3.75 g/d colesevelam HCl. Individuals with LDL-C lowering of ≥5.0% with colesevelam HCl were randomly assigned to one of two groups after a 3-week washout: 1) 25 g/d of an insoluble fraction of partially hydrolyzed SP or 2) 25 g/d TMP. Results Both SP and TMP reduced atherogenic lipoproteins, as indicated by changes in total cholesterol (−7.4% and −3.6%), LDL-C (−10.9% and −5.9%), nonhigh-density lipoprotein cholesterol (−10.8% and −3.9%), and apolipoprotein B (−9.7% and −2.4%), respectively (P < .05 for between group differences except LDL-C, P = .085). No significant increases were observed in either group for fecal bile acids or neutral sterols. Conclusion These results confirm that SP consumption exerts a hypocholesterolemic effect and indicate that TMP elicits a less pronounced response. However, these findings do not support the hypothesis that increased bile acid excretion is an important contributor to the hypocholesterolemic effects of either protein source. Soy protein (SP) and low-fat dairy product consumption have been suggested to have hypocholesterolemic effects, although the responsible mechanisms are poorly understood. This randomized, controlled, parallel arm trial evaluated the effects of an insoluble fraction of SP and total milk proteins (TMPs) with high calcium content on the fasting lipid profile. It also assessed the potential contributions of increased excretion of bile acids and neutral sterols to their lipid-altering effects. Subjects with hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] 100−199 mg/dL) followed the Therapeutic Lifestyle Changes diet for 4 weeks, followed by a 2-week lead-in with 3.75 g/d colesevelam HCl. Individuals with LDL-C lowering of ≥5.0% with colesevelam HCl were randomly assigned to one of two groups after a 3-week washout: 1) 25 g/d of an insoluble fraction of partially hydrolyzed SP or 2) 25 g/d TMP. Both SP and TMP reduced atherogenic lipoproteins, as indicated by changes in total cholesterol (−7.4% and −3.6%), LDL-C (−10.9% and −5.9%), nonhigh-density lipoprotein cholesterol (−10.8% and −3.9%), and apolipoprotein B (−9.7% and −2.4%), respectively (P < .05 for between group differences except LDL-C, P = .085). No significant increases were observed in either group for fecal bile acids or neutral sterols. These results confirm that SP consumption exerts a hypocholesterolemic effect and indicate that TMP elicits a less pronounced response. However, these findings do not support the hypothesis that increased bile acid excretion is an important contributor to the hypocholesterolemic effects of either protein source." @default.
- W2020623384 created "2016-06-24" @default.
- W2020623384 creator A5021440196 @default.
- W2020623384 creator A5032023438 @default.
- W2020623384 creator A5043927669 @default.
- W2020623384 creator A5047700472 @default.
- W2020623384 creator A5074529871 @default.
- W2020623384 creator A5078499434 @default.
- W2020623384 creator A5078705227 @default.
- W2020623384 date "2010-11-01" @default.
- W2020623384 modified "2023-10-17" @default.
- W2020623384 title "Effects of soy protein on lipoprotein lipids and fecal bile acid excretion in men and women with moderate hypercholesterolemia" @default.
- W2020623384 cites W1489548337 @default.
- W2020623384 cites W1907247569 @default.
- W2020623384 cites W1913969393 @default.
- W2020623384 cites W1939165114 @default.
- W2020623384 cites W1953072781 @default.
- W2020623384 cites W1955611966 @default.
- W2020623384 cites W1968417167 @default.
- W2020623384 cites W1989273144 @default.
- W2020623384 cites W1991203386 @default.
- W2020623384 cites W1996592745 @default.
- W2020623384 cites W2000457146 @default.
- W2020623384 cites W2011250392 @default.
- W2020623384 cites W2020518050 @default.
- W2020623384 cites W2029774139 @default.
- W2020623384 cites W2038379576 @default.
- W2020623384 cites W2039172250 @default.
- W2020623384 cites W2041765989 @default.
- W2020623384 cites W2044917349 @default.
- W2020623384 cites W2051358257 @default.
- W2020623384 cites W2054209747 @default.
- W2020623384 cites W2056888959 @default.
- W2020623384 cites W2069898499 @default.
- W2020623384 cites W2070340881 @default.
- W2020623384 cites W2071802081 @default.
- W2020623384 cites W2078519482 @default.
- W2020623384 cites W2080030243 @default.
- W2020623384 cites W2101494642 @default.
- W2020623384 cites W2106002029 @default.
- W2020623384 cites W2110612260 @default.
- W2020623384 cites W2116404316 @default.
- W2020623384 cites W2127130862 @default.
- W2020623384 cites W2129241344 @default.
- W2020623384 cites W2135186555 @default.
- W2020623384 cites W2161425670 @default.
- W2020623384 cites W2163734144 @default.
- W2020623384 cites W2166863746 @default.
- W2020623384 cites W2170728971 @default.
- W2020623384 cites W2188409304 @default.
- W2020623384 cites W2333028705 @default.
- W2020623384 cites W2395913347 @default.
- W2020623384 cites W4234687690 @default.
- W2020623384 cites W4238251256 @default.
- W2020623384 cites W4240735590 @default.
- W2020623384 cites W4300303469 @default.
- W2020623384 cites W69653712 @default.
- W2020623384 doi "https://doi.org/10.1016/j.jacl.2010.09.001" @default.
- W2020623384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21122701" @default.
- W2020623384 hasPublicationYear "2010" @default.
- W2020623384 type Work @default.
- W2020623384 sameAs 2020623384 @default.
- W2020623384 citedByCount "38" @default.
- W2020623384 countsByYear W20206233842012 @default.
- W2020623384 countsByYear W20206233842013 @default.
- W2020623384 countsByYear W20206233842014 @default.
- W2020623384 countsByYear W20206233842015 @default.
- W2020623384 countsByYear W20206233842016 @default.
- W2020623384 countsByYear W20206233842017 @default.
- W2020623384 countsByYear W20206233842018 @default.
- W2020623384 countsByYear W20206233842019 @default.
- W2020623384 countsByYear W20206233842020 @default.
- W2020623384 countsByYear W20206233842021 @default.
- W2020623384 countsByYear W20206233842022 @default.
- W2020623384 crossrefType "journal-article" @default.
- W2020623384 hasAuthorship W2020623384A5021440196 @default.
- W2020623384 hasAuthorship W2020623384A5032023438 @default.
- W2020623384 hasAuthorship W2020623384A5043927669 @default.
- W2020623384 hasAuthorship W2020623384A5047700472 @default.
- W2020623384 hasAuthorship W2020623384A5074529871 @default.
- W2020623384 hasAuthorship W2020623384A5078499434 @default.
- W2020623384 hasAuthorship W2020623384A5078705227 @default.
- W2020623384 hasConcept C10146269 @default.
- W2020623384 hasConcept C126322002 @default.
- W2020623384 hasConcept C134018914 @default.
- W2020623384 hasConcept C151730666 @default.
- W2020623384 hasConcept C185592680 @default.
- W2020623384 hasConcept C2777014122 @default.
- W2020623384 hasConcept C2778163477 @default.
- W2020623384 hasConcept C2779399885 @default.
- W2020623384 hasConcept C2780072125 @default.
- W2020623384 hasConcept C55493867 @default.
- W2020623384 hasConcept C61716771 @default.
- W2020623384 hasConcept C62746215 @default.
- W2020623384 hasConcept C71924100 @default.
- W2020623384 hasConcept C86803240 @default.
- W2020623384 hasConceptScore W2020623384C10146269 @default.
- W2020623384 hasConceptScore W2020623384C126322002 @default.